Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 1.27 CAD Market Closed
Market Cap: 367.2m CAD

Spectral Medical Inc
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Spectral Medical Inc
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Spectral Medical Inc
TSX:EDT
Net Issuance of Debt
CA$9.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Net Issuance of Debt
-$17.8m
CAGR 3-Years
-47%
CAGR 5-Years
-36%
CAGR 10-Years
-43%
Repare Therapeutics Inc
NASDAQ:RPTX
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Net Issuance of Debt
-$12.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Willow Biosciences Inc
TSX:WLLW
Net Issuance of Debt
-CA$927k
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Spectral Medical Inc
Glance View

Market Cap
367.2m CAD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDT Intrinsic Value
HIDDEN
Show

See Also

What is Spectral Medical Inc's Net Issuance of Debt?
Net Issuance of Debt
9.5m CAD

Based on the financial report for Sep 30, 2025, Spectral Medical Inc's Net Issuance of Debt amounts to 9.5m CAD.

What is Spectral Medical Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 1Y
29%

Over the last year, the Net Issuance of Debt growth was 29%.

Back to Top